title: The natural history of a novel, systemic, disseminated model of syngeneic mouse B-cell lymphoma.
abstract: Lymphomas and leukemias, neoplasms of hematopoetic lineage, pose unique challenges that require novel treatment paradigms. The inter-relationship between the immune system and the neoplastic lesion in these diseases dictates that, to evaluate novel therapies, models are needed that mimic human disease in an immunocompetent host. In the present study, we describe a disseminated, syngeneic model of B-cell lymphoma in the Balb/c mouse based upon the A20 cell line. This model mimics aspects of diffuse large B-cell lymphomas in humans, and recapitulates para-spinous tumor growth, bone destruction and nerve root compression, which may complicate disseminated disease. Furthermore, this tumor expresses a key marker of interest, CD40, which is a candidate for tumor-specific vector targeting via current modalities. The present study therefore describes a high-fidelity model of disseminated lymphoma with implications for novel targeted therapeutics. Lymphomas and leukemias, neoplasms of hematopoetic lineage, pose unique challenges that require novel treatment paradigms. The inter-relationship between the immune system and the neoplastic lesion in these diseases dictates that, to evaluate novel therapies, models are needed that mimic human disease in an immunocompetent host. In the present study, we describe a disseminated, syngeneic model of B-cell lymphoma in the Balb/c mouse based upon the A20 cell line. This model mimics aspects of diffuse large B-cell lymphomas in humans, and recapitulates para-spinous tumor growth, bone destruction and nerve root compression, which may complicate disseminated disease. Furthermore, this tumor expresses a key marker of interest, CD40, which is a candidate for tumor-specific vector targeting via current modalities. The present study therefore describes a high-fidelity model of disseminated lymphoma with implications for novel targeted therapeutics.
authors.affiliation: Department of Medicine, University of Alabama at Birmingham, AL 35291, USA.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Passineau
authors.forename: Gene P
authors.initials: GP
authors.lastname: Siegal
authors.forename: Maaike
authors.initials: M
authors.lastname: Everts
authors.forename: Alexander
authors.initials: A
authors.lastname: Pereboev
authors.forename: Darshana
authors.initials: D
authors.lastname: Jhala
authors.forename: Minghui
authors.initials: M
authors.lastname: Wang
authors.forename: Zeng B
authors.initials: ZB
authors.lastname: Zhu
authors.forename: Sangae Kim
authors.initials: SK
authors.lastname: Park
authors.forename: David T
authors.initials: DT
authors.lastname: Curiel
authors.forename: Gina M
authors.initials: GM
authors.lastname: Nelson
mesh_terms: D000818:Animals; D001847:Bone Diseases; D019013:CD40 Antigens / Q000032:analysis; D045744:Cell Line, Tumor; D006801:Humans; D016867:Immunocompromised Host; D016393:Lymphoma, B-Cell / Q000150:complications / Q000473:pathology*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000150:complications / Q000473:pathology*; D051379:Mice; D008807:Mice, Inbred BALB C; D009374:Neoplasms, Experimental / Q000150:complications / Q000473:pathology*; D011843:Radiculopathy; D013125:Spinal Neoplasms; D014185:Transplantation, Isogeneic
chemical_list: D019013:CD40 Antigens